Sentinel Initiative's Potential Shortcomings Illuminated At Avandia Panel
Executive Summary
The recent Avandia safety panel meeting - during which two FDA advisory committees were unswayed by the results of an observational study by one of the agency's own scientists - underscores the challenges that FDA's Sentinel Initiative will have in becoming an essential regulatory tool
You may also be interested in...
PDUFA V: Sentinel, Regulatory Science Upgrades Could Gain User Fee Funding
FDA’s Sentinel Initiative appears to be gaining support through the Prescription Drug User Fee Act, although industry is not interested in blindly pumping user fee revenue into the project.
PDUFA V: Sentinel, Regulatory Science Upgrades Could Gain User Fee Funding
FDA’s Sentinel Initiative appears to be gaining support through the Prescription Drug User Fee Act, although industry is not interested in blindly pumping user fee revenue into the project.
FDA Finds “Comfort Level” With Using Medicare Data For Sentinel Initiative
FDA research into the clinical accuracy and stability over time of Medicare claims data has shown it could be a reliable source of information for active product safety surveillance, according to FDA’s Judy Racoosin, scientific lead for the Sentinel Initiative within the Center for Drug Evaluation and Research.